Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Anti-Infective Agents Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Antimicrobial-Prescribing in Emergency Departments

NCT03349567
View directory record Official record
Conditions
Anti-Bacterial Agents, Respiratory Tract Infections
Interventions
Audit-and-feedback
Behavioral
Lead sponsor
Iowa City Veterans Affairs Medical Center
Federal
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

NCT00441909
View directory record Official record
Conditions
HIV Infections
Interventions
UC-781, UC-781 placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2009 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of IVRs Releasing TFV and LNG

NCT03279120
View directory record Official record
Conditions
Anti-Infective Agents, Anti-Retroviral Agents, Contraceptive Usage
Interventions
TFV/LNG IVR, Placebo
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 26, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

NCT02015637
View directory record Official record
Conditions
Gonorrhea
Interventions
Delafloxacin, Ceftriaxone
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
25
States / cities
Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Topical Vancomycin for Neurosurgery Wound Prophylaxis

NCT02284126
View directory record Official record
Conditions
Infection, Surgery, Nervous System Diseases
Interventions
Vancomycin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

NCT03824795
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
MGB-BP-3
Drug
Lead sponsor
MGB Biopharma Limited
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Miami, Florida • Orlando, Florida • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

NCT01701401
View directory record Official record
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
53
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C

NCT00593151
View directory record Official record
Conditions
Hepatitis C
Interventions
Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
Other · Biological
Lead sponsor
Biolex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Detroit, Michigan • Dallas, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

NCT01297959
View directory record Official record
Conditions
Infections
Interventions
E-101 Solution 300 GU/ml, Saline solution
Drug
Lead sponsor
Excited States, LLC
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
34
States / cities
Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.

NCT01946568
View directory record Official record
Conditions
Bacterial Infections.
Interventions
Dalbavancin
Drug
Lead sponsor
Durata Therapeutics Inc., an affiliate of Allergan plc
Industry
Eligibility
3 Months to 11 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
10
States / cities
Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

NCT00074425
View directory record Official record
Conditions
HIV Infections
Interventions
BufferGel, PRO 2000/5 Gel, Placebo gel
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
3,101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 26, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Acceptability Study of Vaginal Films for HIV Prevention

NCT01231763
View directory record Official record
Conditions
HIV Infections, Anti-Infective Agents
Interventions
No intervention (not applicable)
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission

NCT00021671
View directory record Official record
Conditions
HIV Infections
Interventions
Erythromycin, Nevirapine, Ampicillin sodium, Metronidazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Female only
Enrollment
3,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia

NCT01969799
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Amikacin fosfomycin inhalation solution, Aerosolized placebo
Drug
Lead sponsor
Cardeas Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Los Angeles, California • Gainesville, Florida • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional

ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record

NCT03397433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Information Technology physician assist
Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
9,673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 26, 2026, 4:53 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 26, 2026, 4:53 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Trial of 70% Ethanol Versus Heparin to Reduce the Rate of Central Line Infections in Children With Short Bowel Syndrome

NCT01263574
View directory record Official record
Conditions
Catheter Related Infections, Short Bowel Syndrome
Interventions
70% ethanol
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Double-Blind Study to Evaluate the Safety and Pharmacokinetics of L-Ofloxacin (RWJ 25213) in Subjects With HIV Infection

NCT00002249
View directory record Official record
Conditions
HIV Infections
Interventions
Levofloxacin
Drug
Lead sponsor
R W Johnson Pharmaceutical Research Institute
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections

NCT03840148
View directory record Official record
Conditions
Urinary Tract Infections, Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam), Meropenem
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Buena Park, California • Chula Vista, California • La Mesa, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers

NCT01162486
View directory record Official record
Conditions
Tuberculosis, Tuberculosis, Pulmonary
Interventions
Rifampin & midazolam, rifapentine and midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

NCT01128530
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections
Interventions
JNJ-32729463, linezolid, JNJ-32729463 placebo, linezolid placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
27
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 26, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children

NCT01166945
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate Combination, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
1 Year to 10 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Oct 26, 2026, 4:53 AM EDT